Clinical Trials for Liver Cancer

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable locally advanced or metastatic HCC, Child-Pugh A liver function, and ECOG 0–1 receive rilvegostomig plus bevacizumab, with or without tremelimumab, or atezolizumab plus bevacizumab. Rilvegostomig is an investigational bispecific antibody targeting PD-1 and TIGIT.

ClinicalTrials.gov ID: NCT06921785

Phase II Trial of Zanzalintinib (XL-092) in Combination With Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated unresectable HCC, ECOG 0–1, and adequate organ function receive oral zanzalintinib, an investigational VEGFR/MET/AXL multikinase inhibitor, with durvalumab (anti–PD-L1) and a single priming dose of tremelimumab (anti–CTLA-4). The study establishes a combination dose and assesses tumor response.

ClinicalTrials.gov ID: NCT06698250

Phase II Basket Trial of Ligufalimab (AK117) and Cadonilimab (AK104) in Advanced Hepatobiliary Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic hepatocellular carcinoma or biliary tract cancer that has progressed after anti-PD-1/PD-L1 therapy receive intravenous ligufalimab, an anti-CD47 antibody, plus cadonilimab, a bispecific PD-1/CTLA-4 antibody. Eligibility requires ECOG performance status 0–1; patients with hepatocellular carcinoma must have Child-Pugh A or B7 liver function.

ClinicalTrials.gov ID: NCT06789848

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic HCC, ECOG 0–1, and Child-Pugh A liver function who have failed exactly one prior anti-PD-(L)1–containing regimen receive lenvatinib plus either visugromab and nivolumab or placebos. Visugromab is an investigational antibody that neutralizes GDF-15 to potentially enhance antitumor T-cell activity; nivolumab inhibits PD-1.

ClinicalTrials.gov ID: NCT07219459

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, progressive recurrent or metastatic solid tumors across 13 cohorts receive intravenous ifinatamab deruxtecan, generally every 3 weeks. This investigational antibody–drug conjugate targets B7-H3 (CD276) and delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06330064

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated, measurable pMMR/MSS metastatic colorectal adenocarcinoma without liver metastases are randomized to first-line FOLFIRI plus bevacizumab with or without volrustomig. Volrustomig is an investigational bispecific antibody targeting PD-1 and CTLA-4.

ClinicalTrials.gov ID: NCT06792695

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Children and adults with measurable EBV-positive post-transplant lymphoproliferative disease after solid-organ transplantation (following failure of rituximab with or without chemotherapy) or allogeneic hematopoietic cell transplantation (following rituximab failure) receive intravenous tabelecleucel. This donor-derived T-cell therapy recognizes EBV peptides presented by a compatible HLA molecule and kills EBV-infected cells.

ClinicalTrials.gov ID: NCT03394365

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated, unresectable, locally advanced or metastatic HCC (BCLC B/C), Child-Pugh A or B7 liver function, and ECOG 0–1 are randomized to livmoniplimab, which blocks activation of immunosuppressive TGF-β1 via the GARP–latent TGF-β1 complex, plus the anti–PD-1 antibody budigalimab, or an active control. Controls are atezolizumab/bevacizumab or tremelimumab/durvalumab during dose optimization, and tremelimumab/durvalumab in the subsequent efficacy comparison.

ClinicalTrials.gov ID: NCT06109272

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced, metastatic, or unresectable hepatocellular carcinoma or intrahepatic cholangiocarcinoma and an injectable tumor lesion receive intratumoral VG161 alone or with nivolumab. VG161 is an oncolytic HSV-1 engineered to kill tumor cells and stimulate immunity through IL-12, IL-15, and PD-1/PD-L1 pathway blockade; nivolumab is a PD-1–blocking antibody.

ClinicalTrials.gov ID: NCT05223816

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic HCC that progressed after one PD-1– or PD-L1–containing systemic regimen receive intratumoral RP2 plus atezolizumab (anti–PD-L1) and bevacizumab (anti-VEGF). RP2 is an engineered oncolytic HSV-1 designed to destroy tumors and stimulate immunity through expression of a fusogenic protein, GM-CSF, and an anti–CTLA-4 antibody; patients need Child-Pugh A liver function, ECOG 0–1, and an injectable lesion.

ClinicalTrials.gov ID: NCT05733598